CDKN2A and osteosarcoma: Although osteosarcoma cells with loss of p16INK4A showed on average a lower IC50 to palbociclib (1.4 μM) than cells with normal p16INK4A expression (4.1 μM), this difference was not statistically significant (p = 0.3) (Fig. 4C).